CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...